Helmholtz-Zentrum Fuer Infektionsforschung Gmbh

Helmholtz-Zentrum Fur Infektionsforschung Gmbh

Gesellschaft Fur Biotechnologische Forschung Mbh

Ciba-Geigy Corporation

Medizinische Hochschule Hannover

Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)

Gesellschaft Fur Biotechnologische Forschung Gmbh

Geselllschaft Fuer Biotechnologishce Forschung Mbh (Gbf)

Bristol-Myers Squibb Compnay

Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschung Gmbh

Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie E.v. -Hans-Knöll-Institut- (Hki)

Gerhard Hofle

Heinrich Steinmetz

Hermann Augustiniak

Johannes Paul Pachlatko

Klaus Gerth

Hans Reichenbach

Gerhard Hoefle

Herbert Irschik

Florenz Sasse

Brigitte Kunze

Rolf Jansen

Norbert Bedorf

Wolfram Trowitzsch-Kienast

Rolf Wolfgang Hartmann

Rolf Müller

Johannes P Pachlatko

Andreas Kirschning

Kathrin Mohr

Mostafa Hamed

Franziska Gille

Sascha Baumann

Ritesh Raju

Walid A M Elgaher

Maria Moreno

Edgar Forche

Victor Wray

Dietmar Schomburg

Stephan Hüttel

Brian L Davis

Daniel A Benigni

Hans-Martin Dahse

Jennifer Herrmann

Thomas Leibold

Nicole Glaser

Matthias Keck

Thomas Pietschmann

Markus Nett

Liang Liang Wang

Rolf Mueller

Gerhard H Ofle

Ingo Hardt

Nisar Malek

Mark Brönstrup

Walid A Elgaher

Stephan Huettel

Irene Wagner-Döbler

Dietmar Schummer

Andreas Meyerhans

Ronald Frank

Irina Nickeleit

Roland Frank

Bettina Hinkelmann

Jochen Huehn

Javier Martinez

Juana Diez

Sebastian Schieferdecker

Konrad Viehrig

Frank Surup

Daniel Krug

Walid A M Elhaher

Thomas P Tully

Stephan Huttel

Juliane Gentzsch

George Koutsoudakis

Kirsten Harmrolfs

Amrita Nandan

Tim Sparwasser

Michael Wolling

The present invention provides cystobactamides of formula (I): R&#x2014;Ar-L-Ar-L-Ar-L-Ar-L-Ar&#x2014;Rand the use thereof for the treatment or prophylaxis of bacterial infections.

Crystobactamides

The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.R&#x2014;Ar-L-Ar-L-Ar-L-Ar-L-Ar&#x2014;R&#x2003;&#x2003;(I):

Cystobactamides

The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula. 

The invention provides a compound termed Carolacton having the structure and derivatives thereof for medical use against biofilm formation by bacteria. 

Pharmaceutical composition effective against biofilms

The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular Argyrin and derivatives thereof, preferably Argyrin A, for the treatment of proliferative diseases, such as cancer, as well as the derivatization of said macrocycles.

Use of inhibitors of the degradation of p27, in particular Argyrin and derivatives thereof, for the treatment of proliferative diseases

The present invention relates to epothilones C, D, E, and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.

Epothilones C, D, E, and F, preparation and compositions

The invention relates to a compound of the following general formula (tubulysin) having the following meanings for R, R, R, R, R, R, R, R, R, R, R, R, S, T, U, V, W, X, Y and Z: 

Tubulysins, method for producing the same and tubulysin preparations

The invention concerns compounds which can be obtained by fermenting DSM 6773, especially epothilones A1, A2, A8, A9, B10, C1, C2, C3, C4, C5, C6, C7, C8, C9, D1, D2, D5, G1, G2, H1, H2, I1, I2, I3, I4, I5, I6 and K and trans-epothilones C1 and C2.

Epothilone side components

The present invention relates to epothilones C, D, E and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.

Epothilones C, D, E and F, preparation and compositions

The invention relates to compounds which are obtained by fermenting DSM 6773, especially epothilones A1, A2, A8, A9, B10, C1, C2, C3, C4, C5, C6, C7, C8, C9, D1, D2, D5, G1, G2, H1, H2, I1, I2, I3, I4, I5, I6 and K and trans-epothilones C1 and C2.

Epothilone minor constituents

The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Thiangazole, its preparation, compositions and use thereof

Growing community of inventors

Braunschweig, Germany

Heinrich Steinmetz